Merck and Schering-Plough disagreed with the contention that use of Zetia and Vytorin should be limited.

FORBES: Magazine Article

Merck (nyse: MRK - news - people ) and Schering-Plough (nyse: SGP - news - people ) disagreed with the contention that use of Zetia and Vytorin should be limited.

FORBES: A Backlash Against Vytorin?